Concepedia

Author

Martin Svatoň

Charles UniversityORCID

Also Known As

M. Svaton, M. Svatoň, MARTIN SVATON, MARTIN SVATOŇ, Martin Svaton, Martin Svatoň

80

Publications

473

Citations

12

H-Index

10

Concepts

All Affiliations

Charles UniversityMasaryk UniversityPalacký University OlomoucGenomacUniversity Hospital Brno
MS

About

Martin Svatoň is an author at Charles University specializing in tumor microenvironment, tumor biology, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

49

2

Pathology

2

2

49

3

Cell Biology

1

1

19

4

Cancer Genetics

1

1

19

5

Cancer Therapeutics

1

1

19

Martin Svatoň

×

13

Publications

334

Citations

11

H-Index

YearCitations

Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Petra Zemanová,

Anticancer Research

2020

82

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Martin Svatoň, Milada Zemanová, Jana Skřičková,

Anticancer Research

2018

40

The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy.

Martin Svatoň, Ondřej Fiala, Miloš Pešek,

PubMed

2016

39

Prognostic significance of TIMP-1 in non-small cell lung cancer

Martin Svatoň, Lukáš Řehoř, Vlastimil Kulda,

Lung Cancer

2012

30

Change in Serum Lactate Dehydrogenase Is Associated with Outcome of Patients with Advanced-stage NSCLC Treated with Erlotinib.

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

PubMed

2016

24

Predictive and prognostic significance of sodium levels in patients with NSCLC treated by erlotinib.

Martin Svatoň, Ondřej Fiala, Miloš Pešek,

PubMed

2014

19

Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Ondřej Fiala, Miloš Pešek, Jana Skřičková,

Tumor Biology

2017

19

Combination of Circulating Tumour DNA and<sup>18</sup>F-FDG PET/CT for Precision Monitoring of Therapy Response in Patients With Advanced Non-small Cell Lung Cancer: A Prospective Study

Ondřej Fiala, Jan Baxa, Martin Svatoň,

Cancer Genomics & Proteomics

2022

18

Epidermal Growth Factor Receptor Gene Amplification in Patients with Advanced-stage NSCLC.

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

PubMed

2016

16

Prognostic Significance of Serum Tumor Markers in Patients with Advanced-stage NSCLC Treated with Pemetrexed-based Chemotherapy.

Ondřej Fiala, Miloš Pešek, Jindřich Fínek,

PubMed

2016

15

Page 1